drugset / Trial / NCT00234936

Quality of Life Study With Adalimumab in Rheumatoid Arthritis

NCT00234936

Phase 3 Completed 200 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the ability of adalimumab combined with methotrexate to improve the quality of life in patients with active RA.

Timeline

Start
2003-12
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody
Subject Methotrexate Small molecule

Indications